EMA committee recommends approval for injectable version of Merck's Keytruda-March 2024-www.financetom.com

EMA committee recommends approval for injectable version of Merck's Keytruda

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

EMA committee recommends approval for injectable version of Merck's Keytruda

Sep 20, 2025 11:47 PM

Sept 19 (Reuters) - Merck ( MRK ) said on Friday the

European Medicines Agency's committee has recommended the

approval for a new formulation of its blockbuster cancer

therapy Keytruda that can be administered under the skin.

Previous page： Southern Insider Sold Shares Worth $931,320, According to a Recent SEC Filing Next page： BRIEF-Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Southern Insider Sold Shares Worth $931,320, According to a Recent SEC Filing

Jul 3, 2024

02:24 PM EDT, 07/03/2024 (MT Newswires) -- Sloane N Drake, Executive Vice President, Chief Human Resources Officer, on July 03, 2024, sold 12,000 shares in Southern (SO) for $931,320. Following the Form 4 filing with the SEC, Drake has control over a total of 16,771 shares of the company, with 16,771 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/92122/000095017024081294/xslF345X03/ownership.xml Price: 77.72, Change:...

BRIEF-Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing

Jul 3, 2024

July 3 (Reuters) - Eagle Pharmaceuticals Inc ( EGRX ): * NANTAHALA CAPITAL MANAGEMENT, LLC REPORTS 15.1% PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF JUNE 30- SEC FILING Source text for Eikon: Further company coverage: ...

AbbVie cuts 2024 profit forecast

Jul 3, 2024

July 3 (Reuters) - AbbVie ( ABBV ) said on Wednesday it has cut 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in charges related to acquisition-related expenses. The company now expects adjusted profit in the range of $10.61 to $10.81 per share, compared with its previous forecast of $11.13 and $11.33 per share. (Reporting by...

BRIEF-Diamond Water Origin Supply Chain Technology Group Co., Ltd. Files For U.S. IPO- SEC Filing

Jul 3, 2024

July 3 (Reuters) - * DIAMOND WATER ORIGIN SUPPLY CHAIN TECHNOLOGY GROUP CO., LTD. FILES FOR U.S. IPO- SEC FILING * DIAMOND WATER ORIGIN SUPPLY CHAIN TECHNOLOGY GROUP CO., LTD.: HAVE APPLIED TO LIST ORDINARY SHARES ON NASDAQ CAPITAL MARKET UNDER SYMBOL ZSSY * DIAMOND WATER ORIGIN SUPPLY CHAIN TECHNOLOGY GROUP CO., LTD.: OFFERING 930,000 ORDINARY SHARES PURSUANT TO THIS...